Key result
ACE inhibitors significantly reduced all-cause mortality compared with placebo (RR 0.79; 95% CI 0.63-0.99), whereas AIIRAs did not (RR 0.99; 95% CI 0.85-1.17).
Why the study?
Do ACE inhibitors and AIIRAs reduce mortality and improve renal outcomes in patients with diabetic nephropathy?
Systematic Review (n=7,545)
Do ACE inhibitors and AIIRAs reduce mortality and improve renal outcomes in patients with diabetic nephropathy?
Relative Risk: 0.79 (95% CI 0.63–0.99)
In patients with diabetic nephropathy, ACE inhibitors significantly reduce all-cause mortality compared to placebo, whereas AIIRAs do not, though both agents show similar benefits for renal outcomes.
No takes yet. Share an insight, caveat, or question.
Supports ACEI use for mortality benefit in diabetic nephropathy; confirms renal protection for both classes but differential survival effect.
Strippoli et al. (2004) conducted a systematic review in Diabetic nephropathy (n=7,545). ACE inhibitors vs. Placebo or AIIRAs was evaluated on All cause mortality (RR 0.79, 95% CI 0.63 to 0.99). ACE inhibitors significantly reduced all-cause mortality compared with placebo (RR 0.79; 95% CI 0.63-0.99), whereas AIIRAs did not (RR 0.99; 95% CI 0.85-1.17).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: